- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04735809
Efficacy of a Whole Cell Algae Fermentate on Gut Health and Overall Immune Function in Healthy Adults With Mild Gastrointestinal Issues
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy of a Patented Whole Cell Algae Fermentate on Gut Health in Healthy Adults With Mild Gastrointestinal Issues
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This study is a randomized, placebo-controlled, crossover trial with a screening visit and two test periods separated by a three-week washout period.
At Visit 1, after subjects have provided informed consent, medical history will be reviewed and clinic visit procedures will be performed, including assessments of prior/current medication/supplement use, and evaluations of inclusion/exclusion criteria.Subjects will be dispensed a diet record, gastrointestinal questionnaire, bowel habits diary, upper respiratory symptom questionnaire, and a stool collection kit to complete prior to Visit 2 (week 0).
At Visit 2 (week 0), eligible subjects will return to the clinic. The stool samples will be collected, and the diet record, gastrointestinal questionnaire, and bowel habits diary will be collected. Subjects will also be administered a stress questionnaire and quality of life questionnaire. Eligible subjects will then be randomized to one of two test groups (placebo or active). Subjects will track study product intake using a daily study product log and track daily cold symptoms. Subjects will also be given a gastrointestinal questionnaire, bowel habits diary, upper respiratory symptom questionnaire, and a stool collection kit to complete prior to Visit 3 (week 4).
At Visit 3 (week 4), the stool samples will be collected, and the diet record, gastrointestinal questionnaire, and bowel habits diary will be collected. Subjects will also be administered a stress and quality of life questionnaire. Unused study product will be collected and compliance assessed via unused study product.Subjects will also be given a gastrointestinal questionnaire, bowel habits diary, and a stool collection kit to complete prior to Visit 4 (week 7)
Subjects will then enter the 3-week washout period, during which time no surveys/questionnaires will be kept and will then crossover to the other study product in their test sequence and repeat the Test Period I procedures (at Visit 2 and 3) during Test Period II (Visits 4 [week 7] and 5 [week 11]).
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Illinois
-
Addison, Illinois, Verenigde Staten, 60101
- Biofortis Innovation Services
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject is a male or female, 21-60 years of age
- Subject has a BMI of 18.5-34.9 kg/m2
- Subject reports having mild GI issues
- Subject is willing and able to comply with the collection and storage requirements of the stool samples
- Subject has internet access via computer, phone or other device and is able to maintain internet access throughout the trial in order to complete online daily questionnaires
- Subject is a non-user of all tobacco, smoking products and nicotine products
- Subject is willing to maintain physical activity patterns, body weight, supplements/medications, sleep patterns, and habitual diet throughout the trial.
- Subject has no health conditions that would prevent him from fulfilling the study requirements 9 Subject understands the study procedures and signs forms providing informed consent to participate in the study
Exclusion Criteria:
- Subject has an abnormal laboratory test result(s) of clinical importance at Visit 1
- Subject has a clinically important GI condition that would potentially interfere with the evaluation of the study product
- Subject has a history or presence of uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including type 1 and type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including unstable depression and/or unstable anxiety disorders) or biliary disorders
- Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study products
- Subject has extreme dietary habits (e.g., Atkins diet, very high protein, very high fiber)
- Subject has uncontrolled hypertension
- Subject has a recent (within 6 weeks of Visit 1) diarrhea (defined as ≥3 loose or liquid stools/d)
- Subject has participated in colonoscopy or colonoscopy preparation within 3 months prior to Visit 1
- Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer
- Subject has a history of bariatric surgery for weight reducing purposes
- Subject has had a weight gain or loss of ≥5% body weight within 6 months of Visit 1
- Subject has experienced any major trauma or any other surgical event within three months of Visit 1
- Subject has any signs or symptoms of an active infection (including diarrhea) of clinical relevance within 5 days of Visit 1
- Subject has used antibiotics within 3 months of Visit 1 or throughout study period
- Subject has used medications (over-the-counter or prescription) or dietary supplements known to influence GI function
- Subject has used medications or supplements known to influence immune responses
- Subject is a regular user (>3 times/week) of prescribed anti-inflammatory medications within 30 d of Visit 1
- Subject is a regular user (i.e., >1 time per month) of allergy medications
- Subject has used weight-loss medications
- Subject is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period
- Subject has a recent history of (within 12 months of screening; Visit 1; week -1) or strong potential for alcohol or substance abuse
- Individual has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
Microcystalline Cellulose
|
microkristallijne cellulose
|
|
Experimenteel: Treatment
Whole Cell Algae Fermentate
|
Contains at minimum 50% Beta Glucan
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Gastrointestinal symptom
Tijdsspanne: After 4 weeks of each test period
|
Gastrointestinal Tolerability Questionnaire
|
After 4 weeks of each test period
|
|
Gastrointestinal ease and consistency
Tijdsspanne: After 4 weeks of each test period
|
Bristol Stool Scale
|
After 4 weeks of each test period
|
|
Cold/Flu Symptoms
Tijdsspanne: After 4 weeks of each test period
|
Wisconsin Upper Respiratory Symptom Survey
|
After 4 weeks of each test period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Fecal Microbiome
Tijdsspanne: After 4 weeks of each test period
|
Omnigene-GUT DNA Genotek
|
After 4 weeks of each test period
|
|
Fecal biomarker 1
Tijdsspanne: After 4 weeks of each test period
|
Short Chain Fatty Acid
|
After 4 weeks of each test period
|
|
Fecal biomarker 2
Tijdsspanne: After 4 weeks of each test period
|
Leaky Gut biomarker
|
After 4 weeks of each test period
|
|
Stress Questionnaire
Tijdsspanne: After 4 weeks of each test period
|
Perceived Stress Questionnaire
|
After 4 weeks of each test period
|
|
Quality of Life Questionnaire
Tijdsspanne: After 4 weeks of each test period
|
World Health Organization-Quality of Life Questionnaire
|
After 4 weeks of each test period
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Andrea Lawless, MD, Biofortis Innovation Services
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- BIO-1901
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University Hospital, GhentWervingHealthy Controls Group - Leeftijd en geslacht afgestemd | Herhaaldelijk negatief denkenBelgië
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteWervingHealthy Controls Group - Leeftijd en geslacht afgestemd | Borderline persoonlijkheidsstoornis (BPS)Verenigde Staten
-
Hacettepe UniversityWervingBronchiëctasie Volwassene | Healthy Controls Group - Leeftijd en geslacht afgestemdKalkoen
-
Hasselt UniversityWervingMultiple sclerose | Healthy Controls Group - Leeftijd en geslacht afgestemdBelgië, Italië, Spanje
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Brain and Behavior...WervingOpioïdengebruiksstoornis | Healthy Controls Group - Leeftijd en geslacht afgestemdVerenigde Staten
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University of North Carolina, Chapel HillNational Institute of Neurological Disorders and Stroke (NINDS)WervingMusculoskeletale pijn | Fibromyalgie | Healthy Controls Group - Leeftijd en geslacht afgestemdVerenigde Staten
-
Gulseren Demir KarakilicVoltooidFibromyalgie Syndroom | Healthy Controls Group - Leeftijd en geslacht afgestemdKalkoen
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
-
Abant Izzet Baysal UniversityVoltooidHealthy Controls Group - Leeftijd en geslacht afgestemd | Ziekte van Alzheimer (AD)Turkije (Türkiye)
Klinische onderzoeken op Placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
AkesoNog niet aan het wervenAtopische dermatitisChina
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
CellmedisMedical Network Sp. z o.o.Nog niet aan het werven
-
Texas A&M UniversityNutraboltVoltooidGlucose- en insuline -reactie
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten